SCHEMBL3973667

SCHEMBL3973667

[c]1ccccc1OCc1ccc(-c2ccccc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.48
AGXT P21549 2/20 0.48
GSTP1 P09211 2/20 0.45
FFAR1 O14842 1/20 0.43
TAAR1 Q96RJ0 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
SMPD1 P17405 2/20 0.38
APP P05067 1/20 0.38
CARM1 Q86X55 1/20 0.37
PRMT1 Q99873 1/20 0.37
RXRA P19793 1/20 0.36
RXRB P28702 1/20 0.36
RXRG P48443 1/20 0.36
ABCC4 O15439 1/20 0.36
LMNA P02545 1/20 0.36
GAA P10253 1/20 0.36
TSHR P16473 1/20 0.36
PTGS1 P23219 1/20 0.36
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL95381 0.89 TSHR (0.44) IDO1AGXTLMNAGAATSHR
SCHEMBL7086574 0.84 LMNA (0.48) IDO1MEN1KMT2AAPPLMNA
SCHEMBL27905530 0.82 MAOB (0.42) IDO1AGXTLMNAGAATSHR
SCHEMBL6796911 0.82 MAOB (0.44) AGXTKMT2ACARM1PRMT1LMNA
SCHEMBL27802210 0.82 MAOB (0.46) IDO1MEN1KMT2AAPPRXRA
SCHEMBL1907545 0.82 MAOB (0.43) IDO1AGXTMEN1KMT2AAPP
SCHEMBL5790467 0.82 TP53 (0.40) MEN1KMT2AAPPRXRARXRB
SCHEMBL2451731 0.82 MAOB (0.43) IDO1AGXTMEN1KMT2AAPP
SCHEMBL7383564 0.80 NR4A2 (0.57) RXRARXRBRXRGHPGD
SCHEMBL2451926 0.79 APP (0.49) IDO1AGXTMEN1KMT2AAPP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7501538-B2 Aryl and heteroaryl compounds, compositions and methods of use TRANSTECH PHARMA, INC. (US) 2009-03-10 US claimed
US-20050049310-A1 Aryl and heteroaryl compounds, compositions and methods of use VTVX HOLDINGS I LLC 2005-03-03 US claimed
WO-2005014532-A1 ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE TRANSTECH PHARMA, INC. (US) 2005-02-17 WO claimed
US-7501538-B2 Aryl and heteroaryl compounds, compositions and methods of use TRANSTECH PHARMA, INC. (US) 2009-03-10 US disclosed
US-20050049310-A1 Aryl and heteroaryl compounds, compositions and methods of use VTVX HOLDINGS I LLC 2005-03-03 US disclosed
WO-2005014532-A1 ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE TRANSTECH PHARMA, INC. (US) 2005-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049310-A1 Aryl and heteroaryl compounds, compositions and methods of use EPOR, HBG2, CYP2F1 IDO1 1289/4885AGXT 1072/4885GSTP1 1281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.